AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02468739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganglioside-monosialic acid
Description: Ganglioside-monosialic sodium is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2). The dosages of GM1 are 80mg per day.
Study NCT02468739 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2).
Study NCT00602329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00602329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00602329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV
Study NCT00602329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00602329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV
Study NCT00602329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00602329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV
Study NCT05532085 — intervention group
Intervention type: OTHER
Intervention: Evaluation of pain during voluntary termination of pregnancy with medication following consideration of predictive factors of pain without an established analgesic protocol
Description: Evaluation of the pain felt by women having an abortion by aspiration under local anes!thesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.
Study NCT05532085 — intervention group
Intervention type: OTHER
Intervention: Evaluation of pain during a voluntary medical termination of pregnancy following consideration of predictive factors of pain with an established analgesic protocol
Description: Evaluation of the pain felt by women having a medical abortion following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during a medical abortion will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.
Study NCT05532085 — intervention group
Intervention type: OTHER
Intervention: Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain without an established analgesic protocol
Description: Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.
Study NCT05532085 — intervention group
Intervention type: OTHER
Intervention: Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain with established analgesic protocol
Description: Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.
Study NCT00583258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin (Xatral)
Description: 10 mg PO once a day
Study NCT00583258 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Alfuzosin
Description: 10 mg PO once a day
Study NCT03388320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-CHESS
Description: Use of smartphone application: Addiction Comprehensive Health Enhancement Support System (A-CHESS)
Study NCT00483899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
Study NCT00483899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching GW870086X will be administered by subjects
Study NCT01913990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, Ondansetron, Aprepitant
Description: Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.
Study NCT01913990 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arm A: Standard Anti-emetic regimen
Description: Treating physician's discretion for type of anti-emetic to be prescribed.
Study NCT04314869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus transplantation
Description: Patient will undergo surgery in order to transplant the graft (uterus). After that, a follow-up in order to detect early rejection. After 6 months, embryo transfer will be perfomed. Labour route will be C-Section. Two pregnancies are agreed, and after the second one, a hysterectomy will be performed in order to remove the graft.
Study NCT03955770 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy (HFOT)
Description: HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher\&Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher\&Paykel, New Zealand).
Study NCT03955770 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-flow oxygen therapy (LFOT)
Description: LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).
Study NCT01771705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose adjust group (NFAT)
Description: If the average residual expression of the 3 cytokines is \<20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 60% the CNI daily dose will be increased by 15%.
Study NCT02236507 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 3D high resolution anorectal manometry
Description: Procedure will take about 15 min. During procedure resting, voluntary squeeze, bear down maneuver, cough reflex, ano-anal reflex and Rectoanal Inhibitory Reflex will be obtained, if possible.
Study NCT04947748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral versus intravenous administration of antibacterial treatment
Description: Mode of administration of antibacterial treatment
Study NCT04947748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral versus intravenous administration of antibacterial treatment
Description: Mode of administration of antibacterial treatment
Study NCT02834611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceramide NanoLiposome
Description: Intravenous administration of Ceramide NanoLiposome
Study NCT03925870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: Eligible subjects will be enrolled and receive KN046 (3 mg/kg) monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first
Study NCT01190293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: All patients (previously on an efavirenz-based therapy) will be administered maraviroc at 600mg twice-daily for 2 weeks.
Study NCT00738803 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Description: Total hip replacement typically preformed for hip arthritis
Study NCT03299400 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens sensor
Description: Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
Study NCT02025465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF/FL rate control.~Conversion of intravenous to oral, chronic management will be left to the discretion of the ED or managing medical team.
Study NCT02025465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF rate control.~Conversion of intravenous to oral medication for rate control for chronic management will be left to the discretion of the ED or managing medical team.
Study NCT04238442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A&D TM-2657W oscillometric device
Description: Assessing the accuracy of the A\&D TM-2657W oscillometric device using International Standards Organization validation protocol. This involves comparing the accuracy of the A\&D device to 2 observer mercury auscultation (gold standard).
Study NCT01617668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Description: LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
Study NCT01617668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2
Study NCT01617668 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2
Study NCT03879239 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vibrating capsule
Description: Vibrating Capsule administered 5 times per week
Study NCT03879239 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrating capsule
Description: Vibrating Capsule administered 5 times per week
Study NCT00860223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT00860223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: HKI-272
Study NCT04154033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Topical naltrexone cream (1%)
Study NCT04154033 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Topical placebo cream
Study NCT00620048 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of autologous CD34-positive cells (stem cells)
Description: Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.
Study NCT03200067 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized health care service
Description: Personalized health care service, such as rehabilitation exercise recommendation, lifestyle activity coaching, health data monitoring
Study NCT04590300 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: QUESTIONNAIRES
Description: 1 questionnaire at the beginning of the study, before FTE program~1 questionnaire at the end of FTE
Study NCT02520505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supraovulation clomiphene citrate
Description: Treatment with clomiphene citrate during day 3 to 7 of the menstrual cycle.
Study NCT02520505 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Timed intercourse
Description: Timing intercourse during the fertile window in the menstrual cycle. Patients may also utilize an ovulation predictor kit to determine time of ovulation.
Study NCT02520505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intrauterine Insemination
Description: Intrauterine insemination will be performed \~36 hours after the time the woman ovulates, as determined by an ovulation predictor kit.
Study NCT02849652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ATTOC Intervention
Description: ATTOC is implemented in a systematic 3-phase process with 10 steps to guide sites through cultural change and implementation of evidence-based practice.
Study NCT02849652 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: UC Intervention
Description: Sites randomized to UC will not receive an organizational intervention to address TUD treatment. To ensure standardization across UC sites, study personnel will provide a 1-day training seminar that will include written materials describing recommended treatments for TUD to UC personnel consistent with established treatment guidelines.
Study NCT01436032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Description: IV
Study NCT01436032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine
Description: IV
Study NCT01436032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study NCT04296903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MID-C System
Description: Minimal invasive deformity correction system for the treatment of AIS
Study NCT03456570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone 10 mg
Description: Dydrogesterone 10 mg twice daily
Study NCT03456570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: oral tablets twice daily
Study NCT00760266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks
Study NCT00760266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
Study NCT02223000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIBV 308 SE solution
Study NCT02223000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBV 308 SE capsule 1
Study NCT02223000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBV 308 SE capsule 2
Study NCT03629249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo once daily
Description: Placebo to QAW039 once daily (one tablet blinded placebo to QAW039 150 mg and one tablet blinded placebo to QAW039 450 mg).
Study NCT03629249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039 150 mg once daily
Description: QAW039 150 mg once daily (one tablet of blinded QAW039 150 mg to be given together with one tablet blinded placebo to QAW039 450 mg)
Study NCT03629249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039 450 mg once daily
Description: QAW039 450 mg once daily (one tablet of blinded QAW039 450 mg to be given together with one tablet blinded placebo to QAW039 150 mg)
Study NCT01622998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NicoDerm Patch
Description: Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period~\*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable.
Study NCT01622998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NicoDerm Patch
Description: Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period~\*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable.
Study NCT01622998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorette Inhaler
Description: Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
Study NCT03581448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Restoration During Prosthesis Control
Description: Human subjects who use a robotic arm/hand interface will experience variable sensations of touch over time.
Study NCT01402908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI-88
Description: Lyophilized powder reconstituted to provide 160 mg of PI-88
Study NCT01402908 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose lyophilized powder
Study NCT03104166 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medium Cut-Off (MCO) dialysis membrane
Description: Patients will be treated with a CE-certified dialysis membrane that provide enhanced clearance for middle-sized molecules, call Medium Cut-Off membrane.
Study NCT03104166 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-Flux dialysis membrane
Description: Control: Patients will be treated with a CE-certified High-Flux dialysis membrane.
Study NCT04792944 — intervention group
Intervention type: DRUG
Intervention: Urokinase
Description: Washing the subarachnoid clot induced by a subarachnoid haemorrhage aneurysmal bleeding with urokinase after aneurysm clipping
Study NCT04792944 — intervention group
Intervention type: PROCEDURE
Intervention: Endovascular treatment
Description: Aneurysm treatment through endovascular methods
Study NCT04792944 — intervention group
Intervention type: PROCEDURE
Intervention: Clipping
Description: Surgical clipping of brain aneurysms
Study NCT04792944 — intervention group
Intervention type: PROCEDURE
Intervention: External ventricular drain
Description: Insertion of an external ventricular drain to treat acute hydrocephalus
Study NCT02980978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching
Description: Focus on nutrition, activity and appropriate medication use and adherence
Study NCT06134778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Inspiratory muscle training was performed for six weeks. Athletes performed two daily sessions of 30 forced inspirations followed by long but not maximal expirations, with load adjusted between 50% and 60% of maximum inspiratory pressure, five times a week. A specific device was used for this purpose (Classic, Powerbreathe, United Kingdom), with light or medium resistance adjustment, depending on the subject's maximum inspiratory pressure.
Study NCT04486196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medency Primo Diode Laser Device (Medency, Vicenza, Italy)
Description: Root canals were irradiated with 980 nm diode laser coupled with optical fiber 200 µm with setting at the average power 1.2-W in pulsed mode. 10 seconds irradiation followed by 10 seconds pause, which comprised one lasting cycle.
Study NCT04486196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 2.5% NaOCl, %17 EDTA, Distilled water, 30-gauge, side-opening needle (Canal Clean, Biodent, South Korea),
Description: Final conventional irrigation
Study NCT03371290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: The healthy UE will be positioned in front of the mirror and the paretic UE behind it, enabling the patient to observe the movements of the healthy limb through the mirror, interpreting that image as the affected limb. The MT protocol will be composed of active bimanual exercises of range of motion and functional exercises. Three sets of 15 repetitions will be performed for each exercise with a 20 seconds interval between each series, for 30 minutes. The exercises: 1) Elbow flexion/extension; 2) Wrist flexion/extension in neutral position; 3) Fingers flexion/extension in neutral position; 4) Forearm pronation/supination; 5) Roll the ball with hands; 6) Squeezing the sponge; 7) Drag a towel in anteroposterior direction; 8) Opponency of fingers; 9) Climb the mirror with the fingers (similar to walking the spider).
Study NCT03371290 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Intervention
Description: In the control intervention, patients will be performed the same bimanual activities proposed by the MT protocol, but without the reflector side of the mirror. The mirror will be placed in the same position as the MT intervention. However, the subject will have access to the non-reflective side of the mirror, directly visualizing the movement of his healthy arm.~Both interventions will be performed a single session of MT or control composed of 30 minutes of exercises. The participants who will be first assigned to the MT intervention, after 4-weeks washout period, will be performed the same procedures, but in the control intervention. Likewise, patients who will be first allocated to control intervention, after 4-weeks of washout, will be performed the same procedures, however in MT intervention.
Study NCT04552509 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy
Description: Treatment of prostate cancer with stereotactic body radiation therapy (SBRT)
Study NCT03210636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LapSpace
Description: use of atraumatic laparoscopic retractor for patients undergoing laparoscopic surgery